Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
General19 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News23 hours agoSouth-west Queensland highway closed after truck carrying oxygen cylinders catches fire
-
Noosa News21 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
General22 hours agoBack-to-back rate cuts tipped when Reserve Bank meets